Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03092882 · ClinicalTrials.gov registry record · NA
Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c
A NA study, sponsored by Evidation Health.
- Completed
- Registry status
- NA
- Development phase
- 607
- Enrollment target
NCT03092882: Completed NA study, sponsored by Evidation Health.
NCT03092882 is a NA study that has completed, run by Evidation Health. The registered enrollment target is 607 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03092882, a NA study, has completed, sponsored by Evidation Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 607 participants
- Enrollment target
Study Summary
The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with uncontrolled Type 2 diabetes.
Primary Outcome
Change in A1c from study baseline to study end
Interventions
- BEHAVIORAL Diabetes Self-Management Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 607 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2018-02-07 |
| Phase | NA |
What the finished NCT03092882 record still lists
NCT03092882 is an interventional study that assigns participants to a tested intervention. The registered 607 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Diabetes Self-Management Program is the first listed.
NCT03092882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03092882 about?
NCT03092882 is a clinical study titled "Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c". The Digital Self-Management Program for Medicare Advantage Members with Type 2 Diabetes - Impact on A1c trial is a 26-week long, prospective, intent-to-treat, 2-arm randomized controlled trial that aims to evaluate the impact of the Digital Self-Management Program on A1c levels for individuals with ...
What is the current status of trial NCT03092882?
This trial is currently completed. It is a NA study. The enrollment target is 607 participants. The study started on 2017-03-03. Estimated completion is 2018-02-07.
What interventions are being tested in trial NCT03092882?
The interventions under investigation include: Diabetes Self-Management Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT03092882?
This trial is sponsored by Evidation Health, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03092882's enrollment target sits among peer trials
607 162nd of 2000 higher than 1,839 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02064673 · 608 participants · Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
- NCT06091202 · 608 participants · Phase 3
Tele-Collaborative Outreach to Rural Patients With Chronic Pain
- NCT06098144 · 608 participants · Phase 4
Smoking Cessation Program in the Construction Sector
- NCT02342444 · 606 participants · Phase 4
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI